Portfolio Lab

Sabra Health Care REIT, Inc.

  • Stock
  • Ticker SBRA
  • Nasdaq

Real estate · REITs · USA

$20.39 −0.34%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Sabra Health Care REIT, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

SBRAGlobal equities (VT)

$10,000 grew to $20,957. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −74.9% in 03/2020, measured from the peak in 10/2019. It took 57 months to get back to the old peak.

1-year return
+16.5%
5-year return p.a.
+16.1%
10-year return p.a.
+7.7%
Volatility p.a.
30.0%
Largest decline
−74.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue182184189190212222236250
Net income474066232741-2529
Earnings per share0.200.170.270.090.110.16-0.100.11
Balance sheet
Total assets5,3045,2335,3285,5655,4935,5915,5135,430
Liabilities2,5622,5312,6172,7382,6702,8032,7602,589
Equity2,7412,7022,7112,8252,8222,7862,7512,840
Cash6023952017211723236
Long-term debt2,4182,3942,4802,5912,5292,6652,6262,436
Cash flow
Operating cash flow808081100879886129
Free cash flow808081100879886129

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +41.1%, weakest 2017 at −16.9%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
2 Nov 2026$0.11
3 Aug 2026−$0.10
29 Apr 2026$0.16
12 Feb 2026$0.11
5 Nov 2025$0.09
4 Aug 2025$0.27
5 May 2025$0.17
19 Feb 2025$0.20
31 Oct 2024$0.13
7 Aug 2024$0.10
8 May 2024$0.11
27 Feb 2024$0.07

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€4.8bn
Market cap in trading currency
$5.34bn
Enterprise value
$7.74bn
P/E
72.8
P/S
5.81
P/B
1.88
EV/Sales
8.42
EV/EBITDA
19.0
Earnings yield
1.4%
FCF yield
7.5%

Results (last four quarters)

Revenue
$919m
Gross profit
–
EBITDA
$407m
Net income
$71.5m
Earnings per share
$0.28
Revenue per share
$3.51
Revenue growth
+31.3%
Earnings growth
+26.9%

Profitability

Gross margin
–
Operating margin
19.7%
Net margin
7.8%
Return on equity
2.5%
Return on assets
1.3%

Balance sheet and cash flow

Cash
$36.2m
Cash per share
$0.14
Financial debt
$2.44bn
Debt/equity %
86
Current ratio
–
Book value per share
$10.84
Operating cash flow
$401m
Free cash flow
$401m

Dividend

Dividend yield
7.36%
Dividend (12 months)
$1.50
Yield (12 months)
7.36%
Payout ratio
536%
Ex-dividend date
13 Nov 2026

Shares and trading

Shares outstanding
262m
Volume
3.25m
Avg. volume 3 months
2.47m
Relative volume
1.3

Price and technicals

Price
$20.39
1 day
−0.3%
52-week high
$22.39
52-week low
$17.67
Distance to 52-week high
−8.9%
Distance to 52-week low
+15.4%
Distance to 50-day line
+2.7%
Distance to 200-day line
+1.4%
RSI (14)
52
Volatility 1M
26.5%

Performance

1 week
−0.2%
1 month
+4.0%
3 months
−0.4%
6 months
−1.6%
YTD
+7.7%
1 year
+9.6%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has SBRA performed since 11/2016?

$10,000 grew to $20,957 by 20 Nov 2026, which is +7.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is SBRA?

Volatility was 30.0% per year, measured on monthly returns. The largest decline from a peak was −74.9%, with the low in 03/2020.

How does SBRA compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, SBRA returned +7.7% at 30.0%. The correlation of monthly returns was 0.54; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Sabra Health Care REIT, Inc. (SBRA): Return and risk